Elektronenmikroskopische Befunde an der menschlichen Bronchialschleimhaut nach Behandlung mit Bisolvon

Gieseking, R; Baldamus, U

doi:10.1007/bf02091445

Cited by 24 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this pioneer study, BHC was injected at a dose of 4–20 mg/kg/24 hrs over a period of 2, 4 or 6 days. These observations were later confirmed in human tissue by Gieseking and Baldamus [9]. This later study was conducted on 9 patients with tuberculosis with cavitation or carcinoma before and after partial lung resection.…”

Section: Mechanisms Of Actionmentioning

confidence: 62%

A reappraisal of the mucoactive activity and clinical efficacy of bromhexine

Zanasi

Mazzolini

Kantar

2017

Multidiscip Respir Med

View full text Add to dashboard Cite

Since its introduction to the market in 1963, bromhexine, an over-the-counter drug, has been investigated for its activity in animal models and in humans with diverse respiratory conditions. Bromhexine is a derivate of the Adhatoda vasica plant used in some countries for the treatment of various respiratory diseases. Bromhexine has been found to enhance the secretion of various mucus components by modifying the physicochemical characteristics of mucus. These changes, in turn, increase mucociliary clearance and reduce cough. Principal clinical research studies were primarily developed in an era when stringent methodological approaches and good clinical practices were not developed yet. Clinical studies were conducted mainly in patients with chronic bronchitis and in patients with various respiratory diseases, and demonstrated the efficacy of bromhexine in improving respiratory symptoms. Furthermore, the co-administration of antibiotics with bromhexine amplified the actions of the antibiotic. Although the clinical evidence shows only modest but positive results, bromhexine is indicated for its mucoactive activity. Larger trials with adequate methodology are required to identify when treatment with bromhexine can improve clinical outcomes.

show abstract

Section: Mechanisms Of Actionmentioning

confidence: 62%

A reappraisal of the mucoactive activity and clinical efficacy of bromhexine

Zanasi

Mazzolini

Kantar

2017

Multidiscip Respir Med

View full text Add to dashboard Cite

show abstract

“…According to the findings of Jeffery and Reid [7], the goblet cells form less than 1% of the total epithelial cell population in the rat epithel ium; therefore, Merker's results demon strate rather the response of serous epithel ial cells than of the goblet ones. In an inho- mogeneous group of patients with differ ent respiratory disorders, who were given Bisolvon for varying periods of time, Gieseking and Baldamus [6] did not prove any changes in the airway epithelium which could be ascribed to the function of the mucolytic.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Effect of Three Oral Mucolytics on the Ultrastructure of the Tracheal Epithelium in Rabbits

Konrádová¹,

Vávrová²,

Sůlová³

1985

Respiration

View full text Add to dashboard Cite

The effect of the application of a single oral dose of 100 mg of three mucolytic agents (N-acetylcysteine, carbocysteine and Na-2-mercaptoethane sulphonate) on the ultrastructure of the tracheal epithelium of healthy rabbits was studied. Due to the function of oral mucolytics the goblet cells were overstimulated and injured. Na-2-mer captoethane sulphonate was the least irritating substance. Acetylcysteine produced the most pronounced injury of the goblet cells, followed by rapid differentiation of these cells. Oral administration of all mucolytics studied caused local impairment of mucus flow in the airways.

show abstract

“…The util ity of the latter drugs has been widely de bated [4], Bromhexine is a mucus-modifying drug whose action has been fully documented. It is capable of modulating the activity of the goblet cells, inducing hydrolytic depo lymerization of the mucoprotein fibers and stimulating the activity of the ciliated epithelium [5][6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Italian Multicenter Study on the Treatment of Chronic Obstructive Lung Disease with Bromhexine

Valenti

Marenco²

1989

Respiration

View full text Add to dashboard Cite

237 out-patients suffering from chronic obstructive lung disease (COLD) were selected from 7 Italian clinical centers. They were randomly allocated to either placebo or bromhexine 30 mg b.i.d. p.o., in a double-blind fashion. Sputum volume and quality, facility of expectoration, cough, dyspnea, auscultatory thoracic symptoms, forced expiratory volume, peak expiratory now rate and residual volume were evaluated. Bromhexine showed a statistically significant therapeutic activity in comparison to placebo. This action was rapid, marked and effective in determining a modulation of bronchial secretions.

show abstract

Elektronenmikroskopische Befunde an der menschlichen Bronchialschleimhaut nach Behandlung mit Bisolvon

Cited by 24 publications

References 2 publications

A reappraisal of the mucoactive activity and clinical efficacy of bromhexine

A reappraisal of the mucoactive activity and clinical efficacy of bromhexine

Comparison of the Effect of Three Oral Mucolytics on the Ultrastructure of the Tracheal Epithelium in Rabbits

Italian Multicenter Study on the Treatment of Chronic Obstructive Lung Disease with Bromhexine

Contact Info

Product

Resources

About